nach oben

Erschienen in:

14.11.2019 | Prolactinoma

A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas

verfasst von: B. G. Sant’ Anna, N. R. C. Musolino, M. R. Gadelha, C. Marques, M. Castro, P. C. L. Elias, L. Vilar, R. Lyra, M. R. A. Martins, A. R. P. Quidute, J. Abucham, D. Nazato, H. M. Garmes, M. L. C. Fontana, C. L. Boguszewski, C. B. Bueno, M. A. Czepielewski, E. S. Portes, V. S. Nunes-Nogueira, A. Ribeiro-Oliveira Jr., R. P. V. Francisco, M. D. Bronstein, A. Glezer

Erschienen in: Pituitary | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate the maternal–fetal outcomes of CAB-induced pregnancies in patients with prolactinoma in a large cohort.

Methods

The prevalence of tumor growth, miscarriage, preterm, low birth weight, congenital malformations and impairment in neuropsychological development in children among women treated with CAB were assessed in a Brazilian multicentre retrospective observational study,

Results

We included 194 women with a mean age of 31 (17–45) years, 43.6% presenting microadenomas and 56.4% macroadenomas, at prolactinoma diagnosis. In 233 pregnancies, CAB was withdrawn in 89%, after pregnancy confirmation. Symptoms related to tumor growth occurred in 25 cases, more frequently in macroadenomas. The overall miscarriage rate was 11%, although higher in the subgroup of patients with CAB maintainance after pregnancy confirmation (38% vs. 7.5%). Amongst the live-birth deliveries, preterm occurred in 12%, low birth weight in 6% and congenital malformations in 4.3%. Neuropsychological development impairment was reported in 7% of cases.

Conclusions

Our findings confirm previous results of safety in maternal and fetal outcomes in CAB-induced pregnancies; nevertheless, CAB maintenance after pregnancy confirmation was associated with higher miscarriage rate; result that must be further confirmed.

Miyai K, Ichihara K, Kondo K, Mori S (1986) Asymptomatic hyperprolactinaemia and prolactinoma in the general population–mass screening by paired assays of serum prolactin. Clin Endocrinol 25(5):549–554

Hardy J (1969) Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg. 16:185–217PubMed

Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD et al (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148(3):325–331PubMed

Robert E, Musatti L, Piscitelli G, Ferrari CI (1996) Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 10(4):333–337PubMed

Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331(14):904–909PubMed

Ferrari C, Barbieri C, Caldara R, Mucci M, Codecasa F, Paracchi A et al (1986) Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 63(4):941–945PubMed

Molitch ME (2002) Medical management of prolactin-secreting pituitary adenomas. Pituitary 5(2):55–65PubMed

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288PubMed

Mehta AE, Tolis G (1979) Pharmacology of bromocriptine in health and disease. Drugs 17(5):313–325PubMed

10.

Krupp P, Monka C (1987) Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65(17):823–827PubMed

11.

Molitch ME (2015) Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol 172(5):R205–R213PubMed

12.

Gonzalez JG, Elizondo G, Saldivar D, Nanez H, Todd LE, Villarreal JZ (1988) Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. Am J Med 85(2):217–220PubMed

13.

Hu Y, Ding Y, Yang M, Xiang Z (2018) Serum prolactin levels across pregnancy and the establishment of reference intervals. Clin Chem Lab Med 56(5):803–807PubMed

14.

Scheithauer BW, Sano T, Kovacs KT, Young WF, Ryan N, Randall RV (1990) The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 65(4):461–474PubMed

15.

Persiani S, Sassolas G, Piscitelli G, Bizollon CA, Poggesi I, Pianezzola E et al (1994) Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. J Pharm Sci 83(10):1421–1424PubMed

16.

Bigazzi M, Ronga R, Lancranjan I, Ferraro S, Branconi F, Buzzoni P et al (1979) A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments. J Clin Endocrinol Metab 48(1):9–12PubMed

17.

Beltrame D, Longo M, Mazué G (1996) Reproductive toxicity of cabergoline in mice, rats, and rabbits. Reprod Toxicol 10(6):471–483PubMed

18.

Molitch ME (1999) Management of prolactinomas during pregnancy. J Reprod Med 44(12 Suppl):1121–1126PubMed

19.

Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol 73(2):236–242

20.

Stalldecker G, Mallea-Gil MS, Guitelman M, Alfieri A, Ballarino MC, Boero L et al (2010) Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 13(4):345–350PubMed

21.

Bronstein MD (2005) Prolactinomas and pregnancy. Pituitary 8(1):31–38PubMed

22.

Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R et al (2010) Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 95(6):2672–2679PubMed

23.

Raymond JP, Goldstein E, Konopka P, Leleu MF, Merceron RE, Loria Y (1985) Follow-up of children born of bromocriptine-treated mothers. Horm Res 22(3):239–246PubMed

24.

Bronstein MD, Salgado LR, de Castro Musolino NR (2002) Medical management of pituitary adenomas: the special case of management of the pregnant woman. Pituitary 5(2):99–107PubMed

25.

Karaca Z, Yarman S, Ozbas I, Kadioglu P, Akturk M, Kilicli F et al (2018) How does pregnancy affect the patients with pituitary adenomas: a study on 113 pregnancies from Turkey. J Endocrinol Investig 41(1):129–141

26.

Rastogi A, Bhadada SK, Bhansali A (2017) Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy. Gynecol Endocrinol 33(4):270–273PubMed

27.

Galvão A, Gonçalves D, Moreira M, Inocêncio G, Silva C, Braga J (2017) Prolactinoma and pregnancy—a series of cases including pituitary apoplexy. J Obstet Gynaecol 37(3):284–287PubMed

28.

Araujo B, Belo S, Carvalho D (2017) Pregnancy and Tumor Outcomes in Women with Prolactinoma. Exp Clin Endocrinol Diabetes 125(10):642–648PubMed

29.

Lambert K, Rees K, Seed PT, Dhanjal MK, Knight M, McCance DR et al (2017) Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes. Obstet Gynecol 129(1):185–194PubMed

30.

Glezer A, Bronstein MD (2017) Prolactinomas: how to handle prior to and during pregnancy? Minerva Endocrinol 43(4):423–429PubMed

31.

Molitch ME (1985) Pregnancy and the hyperprolactinemic woman. N Engl J Med 312(21):1364–1370PubMed

32.

Gemzell C, Wang CF (1979) Outcome of pregnancy in women with pituitary adenoma. Fertil Steril 31(4):363–372PubMed

33.

Holmgren U, Bergstrand G, Hagenfeldt K, Werner S (1986) Women with prolactinoma–effect of pregnancy and lactation on serum prolactin and on tumour growth. Acta Endocrinol 111(4):452–459PubMed

34.

Wilcox AJ, Weinberg CR, O'Connor JF, Baird DD, Schlatterer JP, Canfield RE et al (1988) Incidence of early loss of pregnancy. N Engl J Med 319(4):189–194PubMed

35.

Hemminki E, Forssas E (1999) Epidemiology of miscarriage and its relation to other reproductive events in Finland. Am J Obstet Gynecol 181(2):396–401PubMed

36.

Cecatti JG, Guerra GV, Sousa MH, Menezes GM (2010) Abortion in Brazil: a demographic approach. Rev Bras Ginecol Obstet 32(3):105–111PubMed

37.

Sedgh G, Bearak J, Singh S, Bankole A, Popinchalk A, Ganatra B et al (2016) Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends. Lancet 388(10041):258–267PubMedPubMedCentral

38.

Hurault-Delarue C, Montastruc JL, Beau AB, Lacroix I, Damase-Michel C (2014) Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet 290(2):263–270PubMed

39.

Bachelot A, Binart N (2007) Reproductive role of prolactin. Reproduction 133(2):361–369PubMed

40.

Iwama S, Welt CK, Romero CJ, Radovick S, Caturegli P (2013) Isolated prolactin deficiency associated with serum autoantibodies against prolactin-secreting cells. J Clin Endocrinol Metab 98(10):3920–3925PubMedPubMedCentral

41.

Vila G, Akerblad AC, Mattsson AF, Riedl M, Webb SM, Hána V et al (2015) Pregnancy outcomes in women with growth hormone deficiency. Fertil Steril 104(5):1210–7.e1PubMed

42.

Betrán AP, Ye J, Moller AB, Zhang J, Gülmezoglu AM, Torloni MR (2016) The increasing trend in caesarean section rates: global, regional and national estimates: 1990–2014. PLoS ONE 11(2):e0148343PubMedPubMedCentral

43.

Ferreira EC, Pacagnella RC, Costa ML, Cecatti JG (2015) The Robson ten-group classification system for appraising deliveries at a tertiary referral hospital in Brazil. Int J Gynaecol Obstet 129(3):236–239PubMed

44.

Bolognani CV, Reis LBSM, Dias A, Calderon IMP (2018) Robson 10-groups classification system to access C-section in two public hospitals of the Federal District/Brazil. PLoS ONE 13(2):e0192997PubMedPubMedCentral

45.

Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A et al (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 16(6):791–793PubMed

46.

Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol 68(1):66–71

47.

Domingue ME, Devuyst F, Alexopoulou O, Corvilain B, Maiter D (2014) Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol 80(5):642–648

48.

Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R et al (2012) National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 379(9832):2162–2172PubMed

49.

Blanc AK, Wardlaw T (2005) Monitoring low birth weight: an evaluation of international estimates and an updated estimation procedure. Bull World Health Organ 83(3):178–185PubMedPubMedCentral

50.

Kalter H, Warkany J (1983) Medical progress. Congenital malformations: etiologic factors and their role in prevention (first of two parts). N Engl J Med 308(8):424–431PubMed

51.

Glezer A, Bronstein MD (2014) Prolactinomas, cabergoline, and pregnancy. Endocrine 47(1):64–69PubMed

52.

Mitsiakos G (2019) A possible role of GDNF expression by which cabergoline use affects corpus callosum. J Pediatr Neonatal Individ Med 8:e080112

53.

van Gool JD, Hirche H, Lax H, De Schaepdrijver L (2018) Folic acid and primary prevention of neural tube defects: a review. Reprod Toxicol 80:73–84PubMed

54.

Zárate A, Canales ES, Alger M, Forsbach G (1979) The effect of pregnancy and lactation on pituitary prolactin-secreting tumours. Acta Endocrinol 92(3):407–412PubMed

55.

Auriemma RS, Perone Y, Di Sarno A, Grasso LF, Guerra E, Gasperi M et al (2013) Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 98(1):372–379PubMed

56.

Rjosk HK, Fahlbusch R, von Werder K (1982) Influence of pregnancies on prolactinomas. Acta Endocrinol 100(3):337–346PubMed

57.

Crosignani PG, Mattei AM, Scarduelli C, Cavioni V, Boracchi P (1989) Is pregnancy the best treatment for hyperprolactinaemia? Hum Reprod 4(8):910–912PubMed

58.

Crosignani PG, Mattei AM, Severini V, Cavioni V, Maggioni P, Testa G (1992) Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obstet Gynecol Reprod Biol 44(3):175–180PubMed

59.

Huda MS, Athauda NB, Teh MM, Carroll PV, Powrie JK (2010) Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin Endocrinol 72(4):507–511

Titel: A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas
verfasst von: B. G. Sant’ Anna
N. R. C. Musolino
M. R. Gadelha
C. Marques
M. Castro
P. C. L. Elias
L. Vilar
R. Lyra
M. R. A. Martins
A. R. P. Quidute
J. Abucham
D. Nazato
H. M. Garmes
M. L. C. Fontana
C. L. Boguszewski
C. B. Bueno
M. A. Czepielewski
E. S. Portes
V. S. Nunes-Nogueira
A. Ribeiro-Oliveira Jr.
R. P. V. Francisco
M. D. Bronstein
A. Glezer
Publikationsdatum: 14.11.2019
Verlag: Springer US
Schlagwörter: Prolactinoma
Birth
Miscarriage
Pregnancy
Erschienen in: Pituitary / Ausgabe 2/2020
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-019-01008-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey

Effects of cabergoline therapy on serum IGF-1 concentrations in prolactinoma patients

Long-term follow-up for ectopic ACTH-secreting pituitary adenoma in a single tertiary medical center and a literature review

Granulomatous hypophysitis causing compression of the internal carotid arteries reversible with azathioprine and rituximab treatment

Semen quality in hypogonadal acromegalic patients